Abvc biopharma receives u.s. patent for adhd treatment, a $32 billion market

Fremont, ca, nov. 21, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a u.s. patent, application no. 17/120,965, for the use of pdc-1421, a radix polygala (polygala tenuifolia willd) extract, which is used in the company's asset abv-1505, targeting attention deficit/hyperactivity disorder (adhd).
ABVC Ratings Summary
ABVC Quant Ranking